Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nektar Therapeutics Inc. Rose 19% in March

By Brian Feroldi - Apr 8, 2016 at 1:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better-than-expected earnings coupled with a catalyst-filled year send shares in the right direction.


What: Investors in Nektar Therapeutics (NKTR -3.12%), a small-cap biopharma, had a profitable March, Shares rose more than 19% during the month, according to data from S&P Global Market Intelligence.

NKTR Chart

So what: The San Francisco-based company started the month off by reporting fourth-quarter and full-year results that gave its stock a shot in the arm. Revenue came in at $39.37 million during the quarter, far exceeding the $28.82 million that analysts were looking for. The higher-than-predicted revenue helped to slow the company's net loss per share, which was only $0.40 for the period. That was also ahead of the $0.42 loss that Wall Street expected.

During the quarter, the company refinanced a huge slug of its debt, which had the dual effect of lowering its borrowing cost and increasing its cash balance. At year-end, it held more than $308 million in cash on its books.

The stock took a hit when those results were announced, but as the market had more time to digest the results, investors started to bid up shares.

Now what: It seems investors can look forward to a year ahead filled with catalysts. Marketing partner Baxalta has already submitted Adynovate -- a drug used to treat hemophilia A -- for labeling expansion in the U.S. Baxalta believes that Adynovate could also provide a clinical benefit in the pediatric and surgical settings.

Overseas, Nektar and its partners, AstraZeneca and ProStrakan, will continue the worldwide rollout of Movantik/Moventiq for opioid-induced constipation. Nektar has already banked millions in milestone payments from this drug, and it could pull in hundreds of millions more plus double-digit royalties if the drug proves to be a commercial success. 

Looking at Nektar's pipeline, there are several readouts expected during the year that investors should keep an eye on. NKTR-214, an immuno-oncology drug candidate, is currently in phase 1 human trials evaluating its safety and efficacy in treating solid tumors, and the company expects to have top-line data to report in the second half of the year.

Turning to its partnered pipeline drugs, top-line data from two phase 3 trails that are testing Cipro DPI in treating bronchiectasis are expected during the year. Nectar is partnered with Bayer on these trials, and the drug has already received orphan status designation from the Food and Drug Administration. 

Data is also expected by the end of this year from its phase 3 trial of Fovista in treating wet age-related macular degeneration, which has a royalty-bearing licensing agreement with Ophthotech. Given that the drug is expected to be a blockbuster if approved, this is certainly one that Nektar investors should watch.

With two drugs on the market, an improved balance sheet, a huge list of big-named partners, and multiple catalysts coming, it's easy to see why investors sent Nektar's shares higher in March.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$4.03 (-3.12%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.